Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00713193 · ClinicalTrials.gov registry record · Phase 3
Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
A Phase 3 study of Thrombotic Thrombocytopenic Purpura, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00713193: Completed Phase 3 study of Thrombotic Thrombocytopenic Purpura, sponsored by Ohio State University.
NCT00713193 is a Phase 3 study of Thrombotic Thrombocytopenic Purpura that has completed, run by Ohio State University. The registered enrollment target is 26 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00713193, a Phase 3 study of Thrombotic Thrombocytopenic Purpura, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD
Primary Outcome
Number of Participants with Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Cyclosporine
Study Locations (1)
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-11 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 3 |
What the finished NCT00713193 record still lists
NCT00713193 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Thrombotic Thrombocytopenic Purpura appearing as the primary indexed condition, and to 2 interventions - of which Prednisone is the first listed.
NCT00713193 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00713193 about?
NCT00713193 is a clinical study titled "Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)". This research involves the use of immune base therapy as an adjunct to plasma exchange, the present standard of care for thrombotic thrombocytopenic purpura (TTP). Funding source -FDA OOPD
What is the current status of trial NCT00713193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2007-11. Estimated completion is 2017-09-20.
What conditions does trial NCT00713193 study?
This clinical trial studies the following conditions: Thrombotic Thrombocytopenic Purpura.
What interventions are being tested in trial NCT00713193?
The interventions under investigation include: Prednisone (DRUG), Cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00713193?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00713193 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombotic Thrombocytopenic Purpura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00713193's enrollment target sits among peer trials
26 1937th of 2000 higher than 60 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia